Nano Dimension Ltd. (NNDM) announced on February 2 2026 that its Board has adopted a limited‑duration shareholder rights agreement, a classic poison pill that will become active if any entity acquires 9.99 % or more of the company’s ordinary shares without board approval. The agreement is set to expire on February 1 2027, giving the board a one‑year window to evaluate any takeover attempts.
The rights become exercisable only after the 9.99 % threshold is reached, and the exercise price is set at a nominal $0.01 per American Depositary Share (ADS). The record date for ADS holders is February 13 2026, ensuring that only shareholders on record at that time can exercise the rights. The limited‑duration nature of the agreement signals the board’s intent to protect the company’s long‑term interests while remaining open to strategic alternatives.
The move follows the disclosure by Oramed Pharmaceuticals that its CEO, Nadav Kidron, had built a 5 % stake in Nano Dimension and signaled a desire to engage with management on governance and strategy. The rights agreement is therefore a direct response to potential activist pressure and part of a broader structured strategic review the board is conducting to maximize shareholder value amid ongoing cash burn and negative earnings. The board’s statement emphasized that the agreement provides a buffer while the company evaluates any unsolicited offers.
Nano Dimension’s defensive posture comes on the heels of its recent acquisitions of Markforged and Desktop Metal, completed in April 2025. Those deals were aimed at consolidating the company’s digital manufacturing platform and expanding its product portfolio, but they have added integration costs and diluted short‑term profitability. In Q1 2025, the company reported revenue of $14.4 million, up 8 % YoY, but gross margin fell from 46 % to 41 % as it invested heavily in new technology and talent.
By adopting the poison pill, Nano Dimension’s board is effectively buying time to assess whether a hostile bid would truly serve shareholders’ interests or simply entrench management. The agreement also signals to the market that the company is prepared to defend its strategic direction, which could influence potential acquirers’ willingness to pursue a takeover. While the rights agreement does not alter the company’s current financial trajectory, it underscores the board’s commitment to safeguarding long‑term value in a volatile industry.
The board’s decision reflects a cautious but proactive stance: it protects against opportunistic takeovers, provides a structured review period, and aligns with the company’s ongoing efforts to integrate recent acquisitions and manage cash burn. Investors will likely view the move as a stabilizing measure that preserves management’s ability to execute its long‑term strategy without external pressure.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.